{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:50:29Z","timestamp":1792021829317,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013945","name":"Institut de Recherches Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:16:43Z","timestamp":1652293003000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"de la Bigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakia","family":"Felloussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Burbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Maruzzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Ammattatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herlinde","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/092986707780362925","article-title":"Targeting cell cycle kinases for cancer therapy","volume":"14","author":"De C\u00e1rcer","year":"2007","journal-title":"Curr Med Chem"},{"issue":"45","key":"10.1016\/j.ejca.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"19108","DOI":"10.1073\/pnas.0904343106","article-title":"Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells","volume":"106","author":"Janssen","year":"2009","journal-title":"ProcNatlAcadSci USA"},{"key":"10.1016\/j.ejca.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1083\/jcb.132.1.111","article-title":"The Saccharomyces cerevisiae spindle pole body duplication gene MPS1 is part of a mitotic checkpoint","volume":"132","author":"Weiss","year":"1996","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ejca.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/emboj\/21.7.1723","article-title":"Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication","volume":"21","author":"Stucke","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200712028","article-title":"Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores","volume":"181","author":"Tighe","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ejca.2022.04.001_bib6","first-page":"89","article-title":"Cell cycle dependent regulation of the protein kinase TTK","volume":"9","author":"Hogg","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"20232","DOI":"10.1073\/pnas.0710519105","article-title":"Autophosphorylation-dependent activation of human Mps1 is required for the spindle checkpoint","volume":"104","author":"Kang","year":"2007","journal-title":"ProcNatlAcadSci USA"},{"issue":"2","key":"10.1016\/j.ejca.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41568-020-00321-1","article-title":"Aneuploidy as a promoter and suppressor of malignant growth","volume":"21","author":"Vasudevan","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"E63712","DOI":"10.1371\/journal.pone.0063712","article-title":"TTK\/hMPS1 is an attractive therapeutic target for triple-negative breast cancer","volume":"8","author":"Maire","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejca.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molonc.2013.12.018","article-title":"TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers","volume":"8","author":"Gyorffy","year":"2014","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","article-title":"Targeting microtubules by natural agents for cancer therapy","volume":"13","author":"Mukhtar","year":"2014","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.ejca.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","article-title":"Cancer phase I clinical trials: efficient dose escalation with overdose control","volume":"17","author":"Babb","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"issue":"24","key":"10.1016\/j.ejca.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"10255","DOI":"10.1158\/0008-5472.CAN-10-2101","article-title":"Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase","volume":"70","author":"Colombo","year":"2010","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:12Z","timestamp":1760733372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":16,"alternative-id":["S0959804922001708"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}